Dompé farmaceutici S.p.A and the Chinese Academy of Sciences collaborate on in-depth studies of over 50 molecules active against Sars-Cov-2

June 9, 2020

Dompé to Present Phase II Clinical Data for Ladarixin in New-Onset Type 1 Diabetes (T1D) at the American Diabetes Association’s Scientific Sessions

June 8, 2020

AIFA Announces Italian Authorization of Phase 2/3 Clinical Trial of Dompé's Reparixin for the Treatment of Severe Patients with COVID-19 Pneumonia

May 12, 2020

Exscalate4CoV supercomputing platform wins 3 million euro EU funding to hunt for new drugs against Coronavirus pandemic

March 6, 2020

Exscalate4CoV: EU’s supercomputing and life science champions gear-up to fight Coronavirus pandemic

February 17, 2020

The Galien Foundation Debuts 2019 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories

July 15, 2019

EXSCALATE, EPIDEMICS: Exscalate is the world's most powerful supercomputing platform

April 9, 2019

Dompé receives Industry Innovation Award from the National Organization for Rare Disorders for the Development of Oxervate™ eye drops (cenegermin-bkbj), for neurotrophic keratitis

March 12, 2019

Italian researchers abroad and a startup from Rome win the first Call for Ideas by Dompé. The selected projects concern ophthalmology and the wellness area.

February 20, 2019

Dompé receives FDA approval cenegermin eye drops, first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

August 22, 2018

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153